Idiopathic Pulmonary Fibrosis Disease Treatment: Global Markets
Report Scope:
The current report provides detailed coverage of IPF. This report will provide perspective on the drugs and therapies used for the management of IPF, including forecast trends and sales through 2024. Important manufacturers, technologies and factors influencing demand are discussed.
The market has been segregated geographically into the U.S., Japan and five major European markets (Germany, France, Italy, Spain, and the U.K.). For market estimates, data has been provided for the year 2018 as the base year, 2019 and then forecast for 2024.
Report Includes:
The current report provides detailed coverage of IPF. This report will provide perspective on the drugs and therapies used for the management of IPF, including forecast trends and sales through 2024. Important manufacturers, technologies and factors influencing demand are discussed.
The market has been segregated geographically into the U.S., Japan and five major European markets (Germany, France, Italy, Spain, and the U.K.). For market estimates, data has been provided for the year 2018 as the base year, 2019 and then forecast for 2024.
Report Includes:
- An overview of the global markets for idiopathic pulmonary fibrosis (IPF) disease treatment
- Analyses of the global market trends, with corresponding market analysis data for 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Estimation of market size and market share analysis of IPF chronic disease on the basis of type of therapeutics and geography
- Insights into the market trends and opportunities, drivers and restraints, regulatory framework, epidemiology, complications, and prevalence of this chronic lung disease
- Company profiles of the market leading participants within the pharmaceuticals industry
CHAPTER 1 INTRODUCTION
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 DRUG DEVELOPMENT AND APPROVAL PROCESS
Introduction
Drug Discovery Process
Drug Definition
Drug Development Regulations
Classification of Techniques Used in Drug Discovery
High-Throughput Screening
Bioanalytical Instruments for Drug Discovery
Cell-Based Assays and Reagents for Drug Discovery
Proteomics Drug Discovery Tools
Genomics Drug Discovery Tools
Bioinformatics as a Platform for Drug Discovery
Others: Metabolomics, Combinatorial Chemistry, Systems Biology, and Nanotechnology
CHAPTER 4 DISEASE OVERVIEW
Etiology
Pathogenesis
Symptoms
Comorbidities
Risk Factors
Environmental
Genetic
Epigenetic Alterations
Aging
CHAPTER 5 DISEASE MANAGEMENT AND TREATMENT
Diagnosis of Idiopathic Pulmonary Fibrosis
Diagnostic Criteria for IPF
Treatments for IPF
Lifestyle Changes
Oxygen
Medications
Pulmonary Rehabilitation
Lung Transplant
CHAPTER 6 MARKETED DRUGS FOR IDIOPATHIC PULMONARY FIBROSIS
Introduction
Overview of Products
Esbriet Drug Profile
Ofev Drug Profile
CHAPTER 7 PRODUCT FORECAST FOR IDIOPATHIC PULMONARY FIBROSIS
Esbriet (Pirfenidone)
Ofev (Nintedanib)
CHAPTER 8 PRODUCT PIPELINE FOR IDIOPATHIC PULMONARY FIBROSIS
Product Pipeline for Idiopathic Pulmonary Fibrosis
CHAPTER 9 APPENDIX: ACRONYMS
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 DRUG DEVELOPMENT AND APPROVAL PROCESS
Introduction
Drug Discovery Process
Drug Definition
Drug Development Regulations
Classification of Techniques Used in Drug Discovery
High-Throughput Screening
Bioanalytical Instruments for Drug Discovery
Cell-Based Assays and Reagents for Drug Discovery
Proteomics Drug Discovery Tools
Genomics Drug Discovery Tools
Bioinformatics as a Platform for Drug Discovery
Others: Metabolomics, Combinatorial Chemistry, Systems Biology, and Nanotechnology
CHAPTER 4 DISEASE OVERVIEW
Etiology
Pathogenesis
Symptoms
Comorbidities
Risk Factors
Environmental
Genetic
Epigenetic Alterations
Aging
CHAPTER 5 DISEASE MANAGEMENT AND TREATMENT
Diagnosis of Idiopathic Pulmonary Fibrosis
Diagnostic Criteria for IPF
Treatments for IPF
Lifestyle Changes
Oxygen
Medications
Pulmonary Rehabilitation
Lung Transplant
CHAPTER 6 MARKETED DRUGS FOR IDIOPATHIC PULMONARY FIBROSIS
Introduction
Overview of Products
Esbriet Drug Profile
Ofev Drug Profile
CHAPTER 7 PRODUCT FORECAST FOR IDIOPATHIC PULMONARY FIBROSIS
Esbriet (Pirfenidone)
Ofev (Nintedanib)
CHAPTER 8 PRODUCT PIPELINE FOR IDIOPATHIC PULMONARY FIBROSIS
Product Pipeline for Idiopathic Pulmonary Fibrosis
CHAPTER 9 APPENDIX: ACRONYMS
LIST OF TABLES
Table 1: Idiopathic Pulmonary Fibrosis Drug Sales, by Country, Through 2024
Table 2: Main Symptoms of Idiopathic Pulmonary Fibrosis
Table 3: Other Symptoms of Idiopathic Pulmonary Fibrosis
Table 4: Key Drugs Marketed for IPF
Table 5: Esbriet Drug Profile
Table 6: Boehringer Ingelheim GmbH: IPF Product Portfolio
Table 7: Roche: IPF Portfolio
Table 8: Roche: IPF Pipeline Portfolio
Table 9: Ofev Drug Profile
Table 10: Sales of Esbriet for IPF, 2018-2024
Table 11: Number of IDF Patients Using Esbriet, 2018-2024
Table 12: Sales of Ofev for IPF, 2018-2024
Table 13: Number of IPF Patients Using Ofev, 2018-2024
Table 14: Phase III Pipeline Products in Development for IPF
Table 15: Acronyms Used in This Report
Table 1: Idiopathic Pulmonary Fibrosis Drug Sales, by Country, Through 2024
Table 2: Main Symptoms of Idiopathic Pulmonary Fibrosis
Table 3: Other Symptoms of Idiopathic Pulmonary Fibrosis
Table 4: Key Drugs Marketed for IPF
Table 5: Esbriet Drug Profile
Table 6: Boehringer Ingelheim GmbH: IPF Product Portfolio
Table 7: Roche: IPF Portfolio
Table 8: Roche: IPF Pipeline Portfolio
Table 9: Ofev Drug Profile
Table 10: Sales of Esbriet for IPF, 2018-2024
Table 11: Number of IDF Patients Using Esbriet, 2018-2024
Table 12: Sales of Ofev for IPF, 2018-2024
Table 13: Number of IPF Patients Using Ofev, 2018-2024
Table 14: Phase III Pipeline Products in Development for IPF
Table 15: Acronyms Used in This Report
LIST OF FIGURES
Figure 1: Drug Discovery Process
Figure 2: Schematic View of IPF Pathogenesis
Figure 3: Diagnostic Algorithm for IPF
Figure 4: Boehringer Ingelheim GmbH: Annual Revenue, 2015-2019
Figure 5: Boehringer Ingelheim GmbH: Revenue Shares, by Business Unit, 2019
Figure 6: Boehringer Ingelheim GmbH: Revenue Shares, by Region, 2019
Figure 7: Roche: Annual Revenue, 2018 and 2019
Figure 8: Roche: Revenue Share, by Product Category, 2019
Figure 1: Drug Discovery Process
Figure 2: Schematic View of IPF Pathogenesis
Figure 3: Diagnostic Algorithm for IPF
Figure 4: Boehringer Ingelheim GmbH: Annual Revenue, 2015-2019
Figure 5: Boehringer Ingelheim GmbH: Revenue Shares, by Business Unit, 2019
Figure 6: Boehringer Ingelheim GmbH: Revenue Shares, by Region, 2019
Figure 7: Roche: Annual Revenue, 2018 and 2019
Figure 8: Roche: Revenue Share, by Product Category, 2019
